Carrie Cox
Président chez ORGANON & CO.
Fortune : 11 M $ au 30/04/2024
Profil
Mme Carrie S. Cox est présidente du conseil d'administration d'Organon & Co, présidente du conseil d'administration d'Advantagene, Inc, présidente du conseil d'administration de Selecta Biosciences, Inc, directrice indépendante de Cardinal Health, Inc, directrice indépendante de Texas Instruments Incorporated et membre du conseil de surveillance du musée d'archéologie et d'anthropologie de l'université de Pennsylvanie. Elle est membre du conseil d'administration de Cardinal Health, Inc. et de Texas Instruments Incorporated. Mme Cox a été précédemment employée en tant que présidente du conseil d'administration d'Array BioPharma, Inc, présidente du conseil d'administration d'electroCore, Inc, directrice indépendante de Celgene Corp, présidente des produits pharmaceutiques mondiaux et vice-présidente exécutive de Schering-Plough Corp, première vice-présidente de la gestion commerciale mondiale de Pharmacia & Upjohn, Inc, présidente de l'activité mondiale de prescription et vice-présidente exécutive de Pharmacia Corp, membre de l'école de santé publique T.H. Chan de Harvard, directrice de Novartis Corp, présidente de Prism Pharmaceuticals, Inc. et vice-présidente de la santé des femmes de Wyeth-Ayerst Research. Elle a également siégé au conseil d'administration de Humacyte, Inc. et de Renetx Bio, Inc. Elle a obtenu son diplôme de premier cycle au Massachusetts College of Pharmacy & Health Science.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 28/02/2024 | 35 801 ( 0,00% ) | 6 M $ | 30/04/2024 | |
CARDINAL HEALTH, INC.
0,02% | 18/09/2023 | 41 631 ( 0,02% ) | 4 M $ | 30/04/2024 |
0,04% | 18/04/2024 | 7 096 ( 0,04% ) | 148 306 $ | 30/04/2024 |
ORGANON & CO.
-.--% | 08/04/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Carrie Cox
| Sociétés | Poste | Début |
|---|---|---|
| TEXAS INSTRUMENTS INCORPORATED | Directeur/Membre du Conseil | 16/09/2004 |
| ORGANON & CO. | Président | 02/06/2021 |
| University of Pennsylvania Museum of Archaeology & Anthropolog | Corporate Officer/Principal | - |
Anciens postes connus de Carrie Cox
| Sociétés | Poste | Fin |
|---|---|---|
| CARDINAL HEALTH, INC. | Directeur/Membre du Conseil | 15/11/2023 |
| HUMACYTE, INC. | Directeur Général | 01/06/2018 |
| CANDEL THERAPEUTICS, INC. | Président | 15/07/2021 |
| ELECTROCORE, INC. | Président | 31/03/2020 |
| CELGENE | Directeur/Membre du Conseil | 01/11/2019 |
Formation de Carrie Cox
| Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| TEXAS INSTRUMENTS INCORPORATED | Electronic Technology |
| CARDINAL HEALTH, INC. | Distribution Services |
| ELECTROCORE, INC. | Health Technology |
| ORGANON & CO. | Health Technology |
| CANDEL THERAPEUTICS, INC. | Health Technology |
| HUMACYTE, INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
| Wyeth-Ayerst Research | |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Humacyte Global, Inc.
 Humacyte Global, Inc. Medical SpecialtiesHealth Technology Humacyte Global, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. It offers its products to the cardiovascular, cosmetic, soft tissue reconstruction, neurosurgical, and orthopedic markets. The company was founded by Laura E. Niklason, Juliana L. Blum and Shannon L. M. Dahl in 2004 and is headquartered in Durham, NC. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Renetx Bio, Inc.
 Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
| Pharmacia & Upjohn, Inc. | Health Technology |
| University of Pennsylvania Museum of Archaeology & Anthropolog | |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Array BioPharma, Inc.
 Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Prism Pharmaceuticals, Inc.
 Prism Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prism Pharmaceuticals, Inc. manufactures cardiovascular injectables and pharmaceutical products. The firm engages in developing and commercializing branded cardiovascular injectable products which include NEXTERONE. The company was founded by Gilbert R. Gonzales and Cameron Durrant in 2003 and is headquartered in King of Prussia, PA. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
